On Demand 2018 Name That Rash: Serious Drug Rashes and Others (MOC)
Price: $25 members, $35 non-members
Drug-induced rashes are common. Most are benign and resolve shortly after discontinuation of the drug, but certain drug rashes are associated with high risk of morbidity and mortality and must be recognized early and treated promptly.
You can earn up to 1.5 AMA PRA Category 1 Credits™, and up to 1.5 MOC Part II Self-Assessment credits.
- Introduction to Drug Allergy and Benign Skin Rashes
Aleena Banerji, MD
- Contact-induced Drug Eruptions and System Contact Dermatitis
Luz S. Fonacier, MD, FACAAI
- Life-threatening and Systemic Drug Reactions
Robert Sidbury, MD, MPH
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Of the AMA PRA Category 1 Credits™ listed above, the ABAI has designated a maximum of 1.5 credits as meeting the requirements for MOC Part II Self-Assessment.
- Practicing allergist/immunologists
- Allergy/immunology Fellows-in-Training
- Physician assistants
- Nurses and advanced practice nurses
- Allied health professionals
- Primary care physicians
- Other medical professionals
- Recognize drug-induced rashes associated with high risk of morbidity and mortality.
- Identify specific treatments for certain serious drug rashes.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Attendance
- 1.50 MOC